Contacts
Info
Updates from Research and Development at Guy's and St Thomas', including interviews, talks and features.
Guy's & St Thomas' Research Round Up
Guy's & St Thomas' Research Round Up
20 APR 2022 · In this episode of the Guy's and St Thomas' Research Roundup Midwife Hillary Thompson interviews Patient Expert Jeannine Joseph about her experiences contributing to the research process and how her lived experiences have helped shape the TAPS2 clinical trial.
Jeannine tells us about working with the sickle team at Guy's and St Thomas', presenting at study days and conferences, how sickle cell is just starting to get it's voice, and how important it is for patients to get involved in research and have their voices heard.
You can find out more about the TAPS2 trial here: bit.ly/TAPS2site
6 DEC 2021 · Could regular exchange blood transfusions help pregnant women with sickle cell?
In this podcast episode, we hear from Professor Eugene Oteng-Ntim from Guy's and St Thomas' Sickle Cell Clinic team. He is leading a feasibility trial to investigate whether pregnant women with sickle cell disease would be willing to take part in a study where they may have regular exchange blood transfusions throughout their pregnancy, to compare this with normal standard care.
Pregnancy in sickle cell patients is considered ‘high risk’ due to the increased likelihood of experiencing complications. It is unknown whether the most commonly prescribed drugs for the condition are safe to take during pregnancy and therefore cannot be taken, meaning alternative measures to support mother and baby are needed.
Listen on to find out more about sickle cell disease, what the risks are for expectant mothers with sickle cell and how the TAPS2 trial hopes to improve their health outcomes.
Read more about the NIHR-supported TAPS2 study here: https://www.guysandstthomasbrc.nihr.ac.uk/microsites/taps2/
If you want to skip to a specific section in the podcast, check out the time stamps below:
0:00-00:30 – Introducing Professor Eugene Oteng-Ntim
00:30-04:20 – What is SCD and how does it affect pregnant women and unborn children?
04:20-08:50 – What are the treatment options for SCD and is it the same for pregnant women?
08:50-11:44 – What is the TAPS2 trial?
11:45-12:37 – How will the outcomes of the trial benefit women and their children?
20 OCT 2021 · Welcome to our podcast highlighting the practicalities and challenges of transitioning the annual King’s Health Partners Summer School from an in-person to a virtual event. Listen to find out about the pros and cons of online events for student engagement, top tips for both public engagement professionals and researchers, and the overall impact that the Summer School has had.
If you want to skip to a specific section in the podcast, check out the time stamps below:
0:00: Intro from Anna Perman, communications manager for Research & Development at Guy’s and St Thomas’ NHS Foundation Trust
01:03: PPE Manager Claire O’Neill describes the set-up of the live King’s Health Partners Summer School events
05:25: Pros to an online school – Recruitment & hard to reach audiences
10:06: Pros to an online school – Students career development benefits
12:59: Challenges to an online school – Camera interaction
14:28: Challenges to an online school – Changing the method of conversation
17:40: Challenges to an online school – Student social bonding
21:30: Claire’s advice to researchers and PE professionals on developing digital activities
24:15: Dr Mahesh Sangrithi shares his experience delivering the online stem cell research session
30:20: Mahesh’s tips for researchers running an online session
31:36: Evaluation and interpreting feedback
37:12: How has the Summer School impacted research throughout King’s Health Partners
39:25: Concluding thoughts from Anna Perman
Updates from Research and Development at Guy's and St Thomas', including interviews, talks and features.
Information
| Author | Jessica |
| Organization | Jessica |
| Categories | Life Sciences |
| Website | - |
| jessica.sells@gstt.nhs.uk |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
